Rejuvenate Bio has always faced a curious problem: How do you prove a longevity therapy works without waiting decades for humans to age?
The San Diego biotech's answer arrives in the form of a $6 million financing closed in June 2026, paired with a research partnership with Merck Animal Health. It's a dual wager—that gene therapies targeting the biological machinery of aging can work across species, and that man's best friend might reach the clinic years before man does.
VCapital led the round, joined by Merck Animal Health, Kendall Capital Partners, Connecticut Innovations, and Digitalis Ventures. The announcement, made in early June, marks a significant animal health collaboration for Rejuvenate Bio. For a company born from the labs of Harvard geneticist George Church, the pathway through veterinary medicine has become less detour than strategic necessity.
The Companion Animal Gambit
Rejuvenate Bio isn't just hedging its bets—it's running parallel experiments. The fresh capital will push forward gene therapy programs in both animal health and what the company carefully terms "longevity science." At the core sits an approach centered on epigenetic reprogramming, a method that attempts to reset cellular aging markers without fully reverting cells to an embryonic state.
The Merck collaboration focuses on an undisclosed veterinary gene therapy. It follows a June 2022 partnership with Phibro Animal Health targeting canine mitral valve disease, then another in February 2024 for canine osteoarthritis. The pattern is deliberate: dogs age faster, develop similar age-related diseases, and their owners—unlike lab funders—will pay out of pocket for treatments that add years.
On the human side, the company secured a $4 million grant from the California Institute for Regenerative Medicine last July. That funding supports IND-enabling studies for RJB-0402, a gene therapy aimed at DSP-variant arrhythmogenic cardiomyopathy, a rare heart condition. The company describes its approach as "mutation-agnostic," addressing downstream disease drivers—arrhythmias, inflammation, fibrosis—rather than correcting specific genetic errors.
Whether this dual-track strategy accelerates progress or divides focus remains an open question.
Science at the Edge of Skepticism
In February 2024, Rejuvenate Bio published research in Cellular Reprogramming on partial reprogramming outcomes. The study showed that partial reprogramming—using a cocktail of transcription factors known as Oct4, Sox2, and Klf4—extended median remaining lifespan by 109% in very old mice (124 weeks, roughly equivalent to humans in their eighties). Frailty scores improved. Epigenetic age markers rolled back.
Partial reprogramming has been circulating through longevity labs and conferences for years now, building on Nobel-winning work by Shinya Yamanaka. The premise: you can reset a cell's biological clock without pushing it all the way back to stem cell chaos. But reviews published in 2024 in both Nature Communications and Aging Cell remain cautious, highlighting persistent worries about tumor formation. Reprogram too much, and cells might forget not just their age but their function—or worse, their growth limits.
Rejuvenate Bio's mouse data offers a proof point, though translating rodent longevity gains into viable therapies for larger, longer-lived mammals has humbled more than a few biotech ventures.
Church's Long Shadow
The company spun out of George Church's lab at Harvard Medical School and the Wyss Institute, securing an exclusive license for veterinary aging gene therapies in September 2020. Church, a towering figure in synthetic biology and genomics, remains a co-founder and scientific advisor. CEO Daniel Oliver and Chief Scientific Officer Noah Davidsohn, both Church lab alumni, lead day-to-day operations. In January 2023, the company brought on Deborah D. Ascheim, M.D., as chief medical officer—a signal, perhaps, that human trials weren't as distant as they once seemed.
Rejuvenate Bio previously raised over $10 million in a Series A round back in April 2021, led by Kendall Capital Partners. VCapital, returning now to lead the latest financing, clearly sees enough traction to double down. CB Insights pegs the company's valuation at roughly $59.4 million as of April, though such figures are external estimates and should be taken with the usual grain of salt.
The company's LinkedIn profile lists between 11 and 50 employees—a lean team for the ambition at hand.
The Clock, Ticking
What Rejuvenate Bio is really selling isn't just a therapy. It's a timeline argument. If aging is a treatable condition—a malleable process rather than an inevitable decline—then the veterinary market offers a proving ground with shorter development cycles, lower regulatory hurdles, and customers emotionally invested in outcomes.
Dogs live 10 to 15 years. Clinical results arrive faster. Approvals, at least in theory, come easier. And if the science holds, the human applications follow.
Whether that logic persuades regulators, investors, and eventually patients will unfold over the next several years. For now, Rejuvenate Bio is betting that the path to longer human lives might just run through the vet's office first.
